[A20-113] Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
Last updated 20.09.2021
Project no.:
A20-113
Commission:
Commission awarded on 30.11.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Heart and circulation
Adults with symptomatic chronic heart failure with reduced ejection fraction
Hint of non-quantifiable added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2021-03-01.
Federal Joint Committee (G-BA)
2021.05.20 A G-BA decision was published.